Earnings Feed
Start Free
Home/Filings/4/0001209191-06-003143
4//SEC Filing

YAROSHEVSKY GLANVILLE MARY 4

Accession 0001209191-06-003143

CIK 0001128495other
View on SEC.govCompany Profile

Filed

Jan 10, 7:00 PM ET

Accepted

Jan 11, 8:49 PM ET

Size

26.8 KB

Accession

0001209191-06-003143

Insider Transaction Report

Form 4
Period: 2006-01-09
ANADYS PHARMACEUTICALS INCANDS
YAROSHEVSKY GLANVILLE MARY
Senior Director, Human Capital
Transactions
  • Sale

    Common Stock

    2006-01-09$10.20/sh−130$1,326→ 1,196 total
  • Sale

    Common Stock

    2006-01-09$10.11/sh−81$819→ 1,115 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2006-01-09−1,500→ 5,363 total
    Exercise: $2.95From: 2002-04-17Exp: 2011-06-20→ Common Stock (1,500 underlying)
  • Sale

    Common Stock

    2006-01-09$10.15/sh−400$4,060→ 1,926 total
  • Sale

    Common Stock

    2006-10-09$10.21/sh−200$2,042→ 1,726 total
  • Sale

    Common Stock

    2006-01-09$10.16/sh−200$2,032→ 1,526 total
  • Exercise/Conversion

    Common Stock

    2006-01-09$2.95/sh+1,500$4,425→ 1,500 total
  • Sale

    Common Stock

    2006-01-09$10.10/sh−600$6,060→ 900 total
  • Sale

    Common Stock

    2006-01-09$10.13/sh−500$5,065→ 400 total
  • Sale

    Common Stock

    2006-01-09$10.11/sh−300$3,033→ 100 total
  • Sale

    Common Stock

    2006-01-09$10.15/sh−100$1,015→ 0 total
  • Sale

    Common Stock

    2006-01-09$10.14/sh−570$5,780→ 2,326 total
Footnotes (3)
  • [F1]The reported sales were effected pursuant to a trading plan established under Rule 10b5-1 of the Securities and Exchange Act of 1934.
  • [F2]Includes 1,448 shares which were acquired pursuant to the Anadys Pharmaceuticals, Inc. 2004 Employee Stock Purchase Plan on November 15, 2004, includes 933 shares which were acquired pursuant to the Anadys Pharmaceuticals, Inc. 2004 Employee Stock Purchase Plan on May 15, 2005, and includes 1,115 shares which were acquired pursuant to the Anadys Pharmaceuticals, Inc. 2004 Employee Stock Purchase Plan on November 15, 2005.
  • [F3]The option vested and became exercisable over a period of four years. All shares subject to the option have vested and are exercisable as of the date of this filing.

Documents

1 file

Issuer

ANADYS PHARMACEUTICALS INC

CIK 0001128495

→
Entity typeother

Related Parties

1
  • filerCIK 0001283305

Filing Metadata

Form type
4
Filed
Jan 10, 7:00 PM ET
Accepted
Jan 11, 8:49 PM ET
Size
26.8 KB
View on SEC.gov